TY - JOUR
T1 - Successful direct adsorption of lipoproteins (DALI) apheresis during pregnancy in an Omani woman with homozygous familial hypercholesterolemia
AU - Al-Dughaishi, Tamima
AU - Al-Waili, Khalid
AU - Banerjee, Yajnavalka
AU - Sheik, Shahila
AU - Al-Sabti, Hilal
AU - Al-Zakwani, Ibrahim
AU - Al-Mukhaini, Suad
AU - Al Wahaibi, Khalifa
AU - Al-Hinai, Ali T.
AU - Al-Rasadi, Khalid
N1 - Publisher Copyright:
© Al-Dughaishi et al.
PY - 2015
Y1 - 2015
N2 - We report our experience with Direct Adsorption of Lipoproteins (DALI) apheresis in an Omani pregnant woman affected by homozygous familial hypercholesterolemia. To the best of our knowledge this is the first successful pregnancy treated with DALI apheresis. The patient had a history of coronary artery disease, supra-aortic valvular stenosis and severe carotid artery disease with right carotid artery stenting. She was on a regular biweekly DALI apheresis since 2008. In May 2013, she became pregnant and rosuvastatin and ezetimibe were stopped while she continued on DALI apheresis biweekly. This treatment during pregnancy was successful with no major complications. The average low-density lipoprotein cholesterol reduction during therapy was 50%. She spontaneously delivered a healthy male infant (2,400 g) at 37 weeks. We showed that DALI apheresis therapy was safe during pregnancy with a good outcome for both mother and neonate.
AB - We report our experience with Direct Adsorption of Lipoproteins (DALI) apheresis in an Omani pregnant woman affected by homozygous familial hypercholesterolemia. To the best of our knowledge this is the first successful pregnancy treated with DALI apheresis. The patient had a history of coronary artery disease, supra-aortic valvular stenosis and severe carotid artery disease with right carotid artery stenting. She was on a regular biweekly DALI apheresis since 2008. In May 2013, she became pregnant and rosuvastatin and ezetimibe were stopped while she continued on DALI apheresis biweekly. This treatment during pregnancy was successful with no major complications. The average low-density lipoprotein cholesterol reduction during therapy was 50%. She spontaneously delivered a healthy male infant (2,400 g) at 37 weeks. We showed that DALI apheresis therapy was safe during pregnancy with a good outcome for both mother and neonate.
KW - Familial hypercholesterolemia
KW - LDL-apheresis
KW - Low density lipoprotein receptor
KW - Pregnancy
KW - Xanthoma
UR - http://www.scopus.com/inward/record.url?scp=84945975467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945975467&partnerID=8YFLogxK
U2 - 10.2174/1874192401509010114
DO - 10.2174/1874192401509010114
M3 - Article
AN - SCOPUS:84945975467
SN - 1874-1924
VL - 9
SP - 114
EP - 117
JO - Open Cardiovascular Medicine Journal
JF - Open Cardiovascular Medicine Journal
ER -